Xeris Biopharma Holdings Inc expected to post a loss of 17 cents a share - Earnings Preview

Xeris Biopharma Holdings

05/05/2023 19:35

* Xeris Biopharma Holdings Inc  XERS.OQ   XERS.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 9. 
    * The Chicago Illinois-based  company is expected to report 
a
39.4% increase in revenue to $30.765 million from $22.07 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Xeris Biopharma
Holdings
Inc is for a loss of 17 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Xeris
Biopharma
Holdings Inc is $5​, above​ its last closing price of $2.31. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.16       -0.16      -0.10     Beat    36.5
 Sep. 30 2022  -0.17       -0.16      -0.16     Met     3
 Jun. 30 2022  -0.23       -0.23      -0.19     Beat    17.4​
 Mar. 31 2022  -0.26       -0.25      -0.25     Met     1.6
 ​​Dec.        -0.20       -0.24      -0.42     Missed  -72.1
 31 2021                                                
 Sep. 30 2021  -0.35       -0.37      -0.39     Missed  -5.4​
 Jun. 30 2021  -0.30       -0.30      -0.41     Missed  -36.7
 Mar. 31 2021  -0.34       -0.34      -0.30     Beat    12.4
 This summary was machine generated May 5 at 18:35 GMT.  All
figures in US dollars  unless otherwise stated